TIDMIMM
RNS Number : 3310R
Immupharma PLC
14 June 2018
FOR IMMEDIATE RELEASE 14 JUNE 2018
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
ImmuPharma PLC
("ImmuPharma" or the "Company")
Positive results of P140 (Lupuzor(TM) or Forigerimod) published
in the Journal of Autoimmunity
in a model of Chronic Inflammatory Demyelinating Polyneuropathy
(CIDP)
The T cell modulator P140 significantly reduced the disease in
the murine preclinical model
Data provides evidence for the expansion of P140 in an
autoimmune indication with
'Orphan Drug Designation'
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the
specialist drug discovery and development company, is delighted to
provide insight into its positive results from pre-clinical studies
of the P140 peptide for Chronic Inflammatory Demyelinating
Polyneuropathy ('CIDP'), a relapsing-remitting autoimmune-mediated
inflammatory disease of the peripheral nervous system for which
specifically-targeted therapies are still lacking.
The results have been published in the 'Journal of Autoimmunity'
entitled: "An autophagy-targeting peptide to treat chronic
inflammatory demyelinating polyneuropathies". This paper is
available to review on line at the Journal of Autoimmunity:
https://doi.org/10.1016/j.jaut.2018.05.009
This study was headed by Professor Sylviane Muller, inventor of
P140/Lupuzor(TM), ImmuPharma's lead compound for Lupus, a
potentially life threatening auto-immune disease.
It has already been demonstrated by a number of presentations by
the Company that the mechanism of action of P140/Lupuzor(TM) can
potentially be applied to a number of other auto-immune diseases in
addition to Lupus.
Key highlights of the CIDP pre-clinical study include:
-- Macro-autophagy and chaperone-mediated autophagy (CMA), are
significantly altered in non-neuronal cells of the peripheral
nervous system
-- P140/Lupuzor(TM), known to target CMA and successfully used
in pathological settings where CMA markers are overexpressed,
considerably ameliorated the clinical and biological course of the
disease in the CIDP model used
-- P140 displayed prophylactic and therapeutic effects, both in
terms of disease intensity and chronicity, and preserved sciatic
nerves from disease-related damages
-- The findings uncover new disrupted molecular pathways in the
model and provide a proof-of-concept that targeting CMA might
represent a promising therapeutic strategy for treating
inflammatory neuropathies for which no disease-specific treatment
is currently available.
Commenting on this announcement, Professor Sylviane Muller
said:
"Over the last couple of years we have provided further evidence
of the role the P140 peptide can take in the potential treatment of
other autoimmune diseases in addition to Lupus. We are delighted
that these results demonstrate positive pre-clinical data in a
murine model of CIDP, which has no available disease-specific
treatment. We look forward to providing a further update on the
progress of our CIDP programme in due course."
For further information please contact:
+ 44 (0) 20
ImmuPharma PLC (www.immupharma.co.uk) 7152 4080
Tim McCarthy, Chairman
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721
Twitter: @immupharma 413496
Northland Capital Partners Limited (NOMAD &
Joint Broker)
David Hignell, Dugald Carlean, Jamie Spotswood,
Corporate Finance +44 (0)20 3861
Rob Rees, Corporate Broking 6625
Bryan, Garnier & Co. (Joint Broker) +44 (0)20 7332 2500
Phil Walker, Corporate Finance
Dominic Wilson, Sales
Notes to Editors
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a
rare disorder of the peripheral
nerves characterized by gradually increasing sensory loss and
weakness associated with loss of reflexes.
The number of new cases per year of CIDP is about 1-2 per
100,000 people, but as the disease can be present in a person for
years prior to diagnosis, the prevalence reflecting the
accumulation of cases over time may be as high as 9 per 100,000 in
some areas.
CIDP is caused by damage to the covering of the nerves, called
myelin. It can start at any age and is more frequent in men than
women.
CIDP is not self-limiting or spontaneous. Left untreated, 30% of
CIDP patients will progress to wheelchair dependence. Early
recognition and proper treatment can avoid a significant amount of
disability.
To date treatments of CIDP (corticosteroids and intravenous
immunoglobulin ('IVIg')) reduce relapse frequency but are not
curative. Furthermore, corticosteroids may induce severe side
effects over a long time treatment period and IVIg is very
expensive.
ImmuPharma PLC
ImmuPharma is a pharmaceutical development company listed since
2006 on AIM of the London Stock Exchange (AIM: IMM), focusing on
developing novel medicines with high sales potential in specialist
markets with serious unmet need. ImmuPharma is led by a
commercially focused Board and management team with extensive
experience.
Lupuzor(TM)
Lupuzor(TM) (also referred to as Forigerimod, or P140) is
ImmuPharma's lead compound and a potential treatment for lupus (or
Systemic Lupus Erythematosus), a chronic, potentially
life-threatening auto-immune disease. Lupuzor(TM) has a novel
mechanism of action aimed at modulating the body's immune system so
that it does not attack healthy cells, and avoids causing adverse
side effects. It has the potential to halt the progression of the
disease in a substantial proportion of patients.
Lupuzor(TM) was granted Fast Track status by the US FDA and
approval to start Phase III under Special Protocol Assessment (SPA)
comprising of two phase III trials. This SPA was subsequently
amended due to its strong safety profile to allow for a reduced
number of patients in the pivotal Phase III trial thereby reducing
the projected cost and time of development considerably.
The recently completed pivotal Phase III clinical trial was
entitled "A 52-Week, Randomized, Double-Blind, Parallel-Group,
Placebo-Controlled Study to Evaluate the Efficacy and Safety of a
200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With
Systemic Lupus Erythematosus".
Commercial Opportunity
There are an estimated five million people globally suffering
from Lupus, with approximately 1.5 million patients in the US,
Europe and Japan (Source: Lupus Foundation of America). Current
'standard of care' treatments, including steroids and
immunosuppressants, can potentially have either serious side
effects for patients or limited effectiveness, with over 60% of
patients not adequately treated.
P140/Forigerimod in other indications
ImmuPharma together with Professor Sylviane Muller, Lupuzor's
inventor, have presented new evidence supporting Lupuzor's(TM)
Forigerimod / P140 peptide activity in several other major
auto-immune disease indications outside of Lupus. In particular,
the peptide appears to have general effects against chronic
inflammatory indications and pre-clinical evidence supports the
molecule's use in: Neuropsychiatric lupus (NPSLE); Gougerot-Sjögren
syndrome (GSS); Chronic Inflammatory Demyelinating Polyneuropathy
(CIDP); Arthritis; Crohn's Disease and Asthma.
Oncology and Ophthalmology
ImmuPharma's second most advanced pipeline programme,
IPP-204106, is a potential treatment for various cancers and acts
by modulating angiogenesis and proliferation. The programme
involves the development of synthetic peptides, Nucants, which
target certain nuclear proteins such as nucleolin and nucleophosmin
on the surface of cells, with very high affinity and selectivity.
Nucleolin is a protein which controls critical pathways within the
cell. The protein is over-expressed at the surface of dividing
cells which makes its binding with Nucants very attractive because
of its potential selectivity - this is of particular importance in
tumour targeting. We are also investigating its use in age-related
macular degeneration where it has demonstrated positive preclinical
efficacy results, diabetic retinopathy and other ophthalmological
indications.
Metabolism and Diabetes
ImmuPharma's subsidiary 'Ureka' has initiated the development of
a novel and innovative peptide technology platform through the
collaboration with CNRS, gaining access to pioneering research
centred on novel peptide drugs at the University of Bordeaux and
the Institut Européen de Chimie et Biologie (IECB). Jointly,
ImmuPharma and CNRS have filed a new co-owned patent controlling
this breakthrough peptide technology. Ureka's current focus is in
Diabetes Type II (GLP-1 analogues - once a month administration);
Non-Alcoholic Steato-Hepatitis (NASH) and there is also potential
in cancer treatment (protein/protein interaction; P53 gene).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RESGGUGCQUPRGQW
(END) Dow Jones Newswires
June 14, 2018 02:00 ET (06:00 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2024 to May 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From May 2023 to May 2024